Clinical Trial Update: Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas [Phase 1]

View source ↗

Summary

Phase 1 trial update for an Anti-GARP CAR-T cell therapy targeting recurrent Grade 2-4 gliomas (including glioblastoma), currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Glioma
• Glioblastoma
• Low-grade Glioma

Drugs mentioned

• Anti-GARP CAR-T Cell Therapy

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Recurrent Malignant Glioma, Recurrent WHO Grade 3 Glioma | Phase 1 | Status: RECRUITING